HEC-1-A Xenograft Model Service for Endometrial Cancer

The HEC-1-A xenograft model is a well-established preclinical platform for evaluating therapeutic candidates against endometrial adenocarcinoma, enabling robust tumor growth monitoring and pharmacodynamic assessment in immunodeficient hosts. At Alfa Cytology, we provide a comprehensive HEC-1-A Xenograft Model Service for Endometrial Cancer, delivering reproducible tumor-bearing models with integrated endpoint analysis to accelerate your preclinical drug development pipeline.

Overview of HEC-1-A Xenograft Model for Endometrial Cancer

The HEC-1-A xenograft model is a widely adopted cell line-derived xenograft (CDX) system generated by subcutaneous or orthotopic implantation of HEC-1-A human endometrial adenocarcinoma cells into immunodeficient mice (e.g., BALB/c nude mice or NSG mice). Originally established in 1968 from a moderately well-differentiated endometrial adenocarcinoma, HEC-1-A cells exhibit potent tumorigenicity in vivo, forming tumors that histologically recapitulate endometrial carcinoma features. This model has been extensively utilized to evaluate hormone-modulating agents, PI3K/Akt and MAPK/ERK pathway inhibitors, and novel cytotoxic compounds, making it a cornerstone for preclinical endometrial cancer research.

In the HEC-1-A xenograft setting, tumor growth is typically monitored through caliper-based volume measurements and non-invasive imaging modalities such as IVIS bioluminescence when luciferase-transfected cells are employed. The model supports pharmacodynamic readouts including TUNEL apoptosis assays, immunohistochemical staining of EMT markers (e.g., E-cadherin, vimentin), and Western blot analysis of signaling pathway activation (e.g., P-ERK, P-AKT). Its low estrogen receptor status further renders it particularly valuable for testing therapeutic strategies targeting ER-negative endometrial cancers, which are often refractory to endocrine therapy.

Figure 1. Quercetin inhibited proliferation and migration of HEC-1-A cells. (Li, Xiaoqin, et al., 2022)

Cell Line Information: HEC-1-A

HEC-1-A is a well-characterized human endometrial adenocarcinoma cell line with extensive use in gynecological cancer research. Below is a comprehensive summary of its biological and molecular characteristics.

Our Services

Alfa Cytology offers a fully integrated HEC-1-A Xenograft Model Service for Endometrial Cancer, encompassing cell line authentication, tumor implantation, in-life monitoring, and comprehensive endpoint analysis. Our experienced team ensures rigorous quality control at every stage---from STR profiling of cell banks to standardized tumor measurement protocols and histopathological evaluation---providing you with reliable, publication-ready data to support your preclinical development decisions.

Workflow of HEC-1-A Xenograft Model Construction

The construction of the HEC-1-A xenograft model follows a standardized, multi-step workflow designed to ensure reproducible tumor growth and reliable pharmacodynamic readouts. Each phase is executed under strict quality control to maintain model integrity.

1. Cell Line Authentication and Expansion: HEC-1-A cells are recovered from authenticated master cell banks and expanded under adherent culture conditions (37 degrees C, 5% CO2). Short tandem repeat (STR) profiling is performed to confirm cell identity and exclude cross-contamination prior to inoculation.
2. Cell Harvest and Viability Assessment: Cells are harvested at logarithmic growth phase using trypsinization, washed, and resuspended in serum-free medium. Cell viability is assessed by trypan blue exclusion, with only preparations exceeding 95% viability used for implantation.
3. Animal Preparation and Cell Inoculation: Immunodeficient mice (e.g., BALB/c nude or NSG) are acclimatized under specific pathogen-free (SPF) conditions. HEC-1-A cells are mixed with Matrigel or PBS and inoculated subcutaneously into the flank (typically 1 x 10^6-5 x 10^6 cells per mouse) or orthotopically into the uterine horn for site-specific studies.
4. Tumor Establishment and Monitoring: Tumor growth is monitored twice weekly using digital calipers, with tumor volume calculated via the modified ellipsoid formula (V = 0.5 x L x W^2). For luciferase-expressing models, IVIS bioluminescence imaging is performed weekly to track tumor burden non-invasively.
5. Treatment Administration: Once tumors reach the target volume (typically 100-200 mm^3), animals are randomized into treatment and vehicle control groups. Test compounds are administered via the specified route (oral gavage, intraperitoneal, or intravenous) according to the study protocol.
6. Endpoint Analysis and Sample Collection: At study termination, tumors are excised, weighed, and processed for histopathology (H&E staining, IHC), molecular analysis (Western blot, qPCR), and apoptosis assessment (TUNEL assay). Blood and organ samples are collected for toxicity profiling as required.

Figure 2: Schematic workflow illustrating the derivation and construction of the HEC-1-A Xenograft Model at Alfa Cytology.

Case Study-HEC-1-A Xenograft Model Development

In a representative preclinical study, HEC-1-A cells were implanted subcutaneously into BALB/c nude mice to evaluate the anti-tumor efficacy of a novel PI3K/Akt pathway inhibitor. Tumors were established successfully within 10-14 days post-inoculation, with mean tumor volumes reaching 150 mm^3 at the time of randomization. Treatment administration over a 3-week period resulted in significant tumor growth suppression compared to vehicle controls, accompanied by increased apoptotic indices as confirmed by TUNEL staining and reduced P-AKT levels in tumor lysates. These findings demonstrate the utility of the HEC-1-A xenograft model in validating targeted therapeutic strategies for endometrial cancer. (Specific data parameters are available upon request and can be customized to align with client study objectives.)

Why Choose Alfa Cytology?

Alfa Cytology is committed to delivering high-quality, reproducible preclinical tumor models with rigorous scientific oversight. Our HEC-1-A xenograft service is designed to meet the demanding standards of modern drug discovery programs.

• Authenticated cell banks with STR profiling and mycoplasma screening to ensure model fidelity.
• Standardized protocols optimized for consistent tumor take rates and growth kinetics across studies.
• Flexible study designs accommodating subcutaneous, orthotopic, and metastatic model configurations.
• Comprehensive endpoint analysis including histopathology, immunohistochemistry, molecular profiling, and toxicity assessment.
• Dedicated project management with regular progress updates and transparent data reporting.
• Competitive timelines and cost-effective pricing tailored to biotech and pharmaceutical research needs.

Contact Us

Ready to advance your endometrial cancer therapeutic program with a validated HEC-1-A xenograft model? Contact us today to discuss your study requirements, timeline, and custom endpoint needs. Our scientific team is standing by to help you design a robust preclinical strategy that delivers actionable data. Reach out to us now and let Alfa Cytology be your trusted partner in preclinical oncology research.

For research use only. Not intended for any clinical use.